Table 6.
Cancer nanomedicine liposomal formulation in the treatment or management of breast cancer.
| Brand Name | Therapeutic Agent | Clinical Trial Phase | Company Name | Reference |
|---|---|---|---|---|
| Doxil | DOX | Approved | Sequus Pharmaceuticals Inc. | [68] |
| LipoDox | DOX | Approved | Sun Pharmaceutical Industries Ltd. | [69] |
| dHER2+AS15 | HER2 antigen | Phase 1/Phase 2 | GlaxoSmithKline | [75] |
| Lipoplatin | Cisplatin | Phase III | Regulon Inc. | [71] |
| EndoTAG1 | Paclitaxel | Completed | MediGene | [72] |
| DPX-0907 | Multicancer-associated antigens | Completed | ImmunoVaccine Technologies | [73,74] |
| LEM-ETU | Mitoxantrone | Phase I | NeoPharm Inc | [75,76] |
| Myocet™ | DOX | Approved | Elan Pharma | [77] |
| LEP-ETU | Paclitaxel | Phase II | NeoPharm Inc | [78] |
| ThermoDox™ | DOX | Phase III | Celsion | [79] |
| MM-302 | DOX | Phase 1 | Merrimack Pharmaceuticals | [80] |